Daratumumab (Dara) is the first-in-class human-specific anti-CD38 mAb approved for the treatment of multiple myeloma (MM). Although recent data have demonstrated very promising results in clinical practice and trials. some patients do not achieve a partial response. and ultimately all patients undergo progression. https://chefesquipmenters.shop/product-category/insulated-creamers/
Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
Internet 14 minutes ago eetfgowjxd1zy9Web Directory Categories
Web Directory Search
New Site Listings